Detecting autoantibodies provides foundational information for the diagnosis of most
autoimmune diseases. An important pathophysiological distinction is whether …

Autoimmune diseases with B cell–directed therapeutics approved by the US Food and Drug
Administration are surprisingly diverse in clinical manifestations and pathophysiology. In this …

Background B-cell anomalies play a role in the pathogenesis of membranous nephropathy.
B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine …

Kidney biopsy is the gold standard to diagnose membranous nephropathy (MN).
Approximately 70%-80% of patients with primary MN have anti-phospholipase A2 receptor …

Results Remissions occurred in 18 (64%) versus eight (30%) from the NICE and GEMRITUX
cohort (P= 0.02) at month 6, respectively, and in 24 (86%) versus 18 (67%) participants (P …

Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare
podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the …

Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-
antibodies targeting podocyte antigens resulting in activation of complement and damage to …

Membranous nephropathy (MN) is one of the most common causes of non-diabetic
nephrotic syndrome in adults. About 80% of cases are renal limited (primary MN) and 20 …

Idiopathic membranous nephropathy (IMN) as a single organ autoimmune disease is a main
cause of nephrotic syndrome in adults which is determined through autoantibodies to …

Autoantibodies against phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type 1
domain-containing 7A (THSD7A) are emerging as biomarkers to classify membranous …